GWM
GILD icon

Geneos Wealth Management’s Gilead Sciences GILD Stock Holding History

Geneos Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.85M Buy
46,311
+107
+0.2% +$14.1K 0.12% 197
2026
Q1 		$6.44M Buy
46,204
+533
+1% +$74.6K 0.15% 161
2025
Q4 		$5.61M Sell
45,671
-2,429
-5% -$295K 0.14% 189
2025
Q3 		$5.34M Sell
48,100
-2,501
-5% -$284K 0.14% 193
2025
Q2 		$5.61M Sell
50,601
-48,035
-49% -$5.11M 0.14% 183
2025
Q1 		$11.3M Buy
98,636
+40,872
+71% +$4.22M 0.16% 153
2024
Q4 		$5.34M Buy
57,764
+297
+0.5% +$26.7K 0.19% 124
2024
Q3 		$4.82M Buy
57,467
+11,173
+24% +$853K 0.18% 134
2024
Q2 		$3.18M Sell
46,294
-14,494
-24% -$967K 0.14% 171
2024
Q1 		$4.45M Sell
60,788
-2,477
-4% -$190K 0.2% 127
2023
Q4 		$5.13M Sell
63,265
-16,244
-20% -$1.26M 0.25% 99
2023
Q3 		$5.96M Buy
79,509
+2,124
+3% +$163K 0.31% 77
2023
Q2 		$5.96M Buy
77,385
+9,764
+14% +$779K 0.31% 75
2023
Q1 		$5.61M Sell
67,621
-10,603
-14% -$878K 0.34% 67
2022
Q4 		$6.72M Buy
78,224
+9,751
+14% +$772K 0.41% 49
2022
Q3 		$4.22M Sell
68,473
-2,259
-3% -$142K 0.29% 81
2022
Q2 		$4.41M Sell
70,732
-5,943
-8% -$368K 0.22% 111
2022
Q1 		$4.56M Buy
76,675
+61,298
+399% +$3.92M 0.2% 123
2021
Q4 		$1.12M Sell
15,377
-766
-5% -$52.8K 0.04% 368
2021
Q3 		$1.11M Buy
16,143
+7
+0% +$492 0.04% 355
2021
Q2 		$1.12M Sell
16,136
-4,047
-20% -$270K 0.04% 334
2021
Q1 		$1.28M Buy
20,183
+64
+0.3% +$4.13K 0.04% 365
2020
Q4 		$1.1M Buy
20,119
+6,154
+44% +$371K 0.04% 328
2020
Q3 		$869K Buy
13,965
+9,009
+182% +$625K 0.05% 317
2020
Q2 		$369K Buy
4,956
+2,312
+87% +$177K 0.02% 485
2020
Q1 		$196K Sell
2,644
-985
-27% -$68.1K 0.01% 614
2019
Q4 		$239K Sell
3,629
-164
-4% -$10.7K 0.01% 630
2019
Q3 		$238K Sell
3,793
-107
-3% -$7K 0.01% 595
2019
Q2 		$263K Sell
3,900
-546
-12% -$35.9K 0.02% 582
2019
Q1 		$289K Sell
4,446
-2,990
-40% -$199K 0.02% 541
2018
Q4 		$466K Sell
7,436
-2
-0% -$140 0.03% 393
2018
Q3 		$578K Buy
7,438
+2,179
+41% +$165K 0.04% 354
2018
Q2 		$372K Sell
5,259
-895
-15% -$63.2K 0.03% 386
2018
Q1 		$463K Sell
6,154
-4,515
-42% -$359K 0.04% 321
2017
Q4 		$764K Buy
10,669
+150
+1% +$11.4K 0.07% 251
2017
Q3 		$852K Sell
10,519
-249
-2% -$19K 0.08% 222
2017
Q2 		$762K Buy
10,768
+70
+0.7% +$4.66K 0.08% 226
2017
Q1 		$726K Sell
10,698
-1,512
-12% -$106K 0.08% 215
2016
Q4 		$874K Buy
12,210
+4,418
+57% +$328K 0.12% 175
2016
Q3 		$616K Sell
7,792
-234
-3% -$19K 0.08% 216
2016
Q2 		$682K Buy
8,026
+565
+8% +$50.1K 0.1% 192
2016
Q1 		$702K Buy
+7,461
New +$673K 0.11% 189

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geneos Wealth Management's GILD Position: Q2 2026 in Review

Geneos Wealth Management increased its Gilead Sciences (GILD) stake by 0.23% in Q2 2026, buying an estimated $14.1K and bringing the position to 46,311 shares worth $5.85M. The position accounts for 0.12% of the portfolio, ranked #197.

Geneos Wealth Management first reported a position in GILD in Q1 2016 and has held it in 42 quarters since. The position peaked at $11.3M in Q1 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Geneos Wealth Management held 46,311 shares of Gilead Sciences worth $5.85M as of Q2 2026.
  • Geneos Wealth Management bought 107 Gilead Sciences shares in Q2 2026, an estimated $14.1K.
  • Gilead Sciences made up 0.12% of Geneos Wealth Management's portfolio in Q2 2026, its #197 holding.
  • Geneos Wealth Management first reported a position in Gilead Sciences in Q1 2016 and has held it in 42 quarters since.
  • Geneos Wealth Management's Gilead Sciences position peaked at $11.3M in Q1 2025.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.